Comparing two conditioning regimens for stem cell transplant in older adults
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial compares two different chemotherapy conditioning regimens (treatments given before a stem cell transplant) to see which works better for older adults with certain blood cancers. The goal is to make the transplant safer and more effective for people aged 60 to 75.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 60 and 75 years old.
- You have acute myeloid leukaemia (AML) in first complete remission or myelodysplastic syndrome (MDS).
- This is your first stem cell transplant (also called a bone marrow transplant).
- You are generally well enough to do daily activities (a score of 0 to 2 on a standard scale).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests adding venetoclax to the usual chemotherapy (fludarabine and melphalan) given before a stem cell transplant for older adults with AML or MDS. The goal is to see if the combination helps prevent the disease from coming back after transplant.
This trial looks back at how older adults with acute myeloid leukemia (AML) did when treated with either standard chemotherapy or a newer combination of venetoclax and decitabine, before a stem cell transplant. The goal is to see which treatment may lead to better outcomes.
This trial compares two drug combinations used before a stem cell transplant to see which is safer and more effective for people with acute myeloid leukemia (AML) that is in remission but still has minimal residual disease (MRD). The goal is to help prevent the leukemia from coming back after transplant.
This trial tests a special conditioning regimen (VA) before a stem cell transplant for older patients with higher-risk myelodysplastic syndrome (MDS). It aims to make the transplant safer and more effective for this group.
This trial tests whether a reduced-intensity stem cell transplant or venetoclax-based pills work better for patients aged 60-75 with high-risk acute myeloid leukemia who are already in remission.
This trial tests a special combination of chemotherapy drugs (called a conditioning regimen) given before a half-matched stem cell transplant for older adults with acute myeloid leukemia (AML) in their first remission. The goal is to make the transplant safer and more effective for people aged 55 to 75.
Hear when a new Older Patients trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.